checkAd
    Startseite > Aktien > MiNK Therapeutics > Nachrichten
    MiNK Therapeutics Aktie
    0,9700
     
    USD
    -2,02 %
    -0,0200 USD
    Letzter Kurs 25.05.24 Nasdaq
    0,9501
     
    USD
    5.800 STK
    Geldkurs 24.05.24
    0,9700
     
    USD
    1.100 STK
    Briefkurs 24.05.24
    ISIN: US6036931029 · WKN: A3C5HZ · SYM: INKT · USA

    Neueste Nachrichten

    MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
    22.05.24 · globenewswire · MiNK Therapeutics
    MiNK Reports First Quarter 2024 Results
    14.05.24 · globenewswire · MiNK Therapeutics
    MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
    13.05.24 · globenewswire · MiNK Therapeutics
    MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
    30.04.24 · globenewswire · MiNK Therapeutics
    MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
    08.04.24 · globenewswire · MiNK Therapeutics
    MiNK Reports Fourth Quarter and Year-End 2023 Results
    21.03.24 · globenewswire · MiNK Therapeutics
    MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
    07.03.24 · globenewswire · MiNK Therapeutics
    MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
    06.03.24 · globenewswire · MiNK Therapeutics
    First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
    14.02.24 · globenewswire · MiNK Therapeutics
    MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
    06.02.24 · globenewswire · MiNK Therapeutics
    MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
    30.01.24 · globenewswire · MiNK Therapeutics
    ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
    20.12.23 · globenewswire · MiNK Therapeutics